Epigenomics AG
ISIN: DE000A37FT41
WKN: A37FT4
26 January 2024 01:16PM

EQS-News: Epigenomics AG: Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD)

Epigenomics AG · ISIN: DE000A37FT41 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 1824185

EQS-News: Epigenomics AG / Key word(s): Personnel
Epigenomics AG: Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD)

26.01.2024 / 13:16 CET/CEST
The issuer is solely responsible for the content of this announcement.


Epigenomics AG: Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD)

Berlin, Germany, January 26, 2024 – Dr Heikki Lanckriet (PhD) has informed the competent bodies of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”) that he resigned as a member of the Company's Supervisory Board with effect as of 22 February 2024. The Supervisory Board will seek to find a suitable successor as member of the Company's Supervisory Board and arrange for his/her appointment by court order in accordance with the statutory provisions.

The chairwoman of the Supervisory Board, Dr Helge Lubenow, thanks Dr Heikki Lanckriet (PhD) for his commitment and dedication to the company and its employees.

 

Contact:
Company
Epigenomics AG, Bertha-Benz-Strasse 5, 10557 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email: contact@epigenomics.com

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, Email: ir@epigenomics.com


Note on forward-looking statements

This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.

 



26.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Epigenomics AG
Bertha-Benz-Straße 5
10557 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A37FT41
WKN: A37FT4
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1824185

 
End of News EQS News Service

1824185  26.01.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1824185&application_name=news&site_id=boersengefluester_html

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 1,53 1,13 0,84 6,20 0,49 0,34 0,00
EBITDA1,2 -12,78 -14,16 -11,09 -1,94 -11,30 -2,91 0,00
EBITDA-Margin3 -835,29 -1.253,10 -1.320,24 -31,29 -2.306,12 -855,88 0,00
EBIT1,4 -12,90 -14,67 -11,63 -2,35 -12,05 -4,50 0,00
EBIT-Margin5 -843,14 -1.298,23 -1.384,52 -37,90 -2.459,18 -1.323,53 0,00
Net Profit (Loss)1 -12,69 -17,02 -11,69 -2,43 -12,02 -4,46 0,00
Net-Margin6 -829,41 -1.506,20 -1.391,67 -39,19 -2.453,06 -1.311,77 0,00
Cashflow1,7 -10,35 -13,51 -9,57 -4,15 -12,02 -5,71 0,00
Earnings per share8 -75,20 -73,00 -40,40 -4,40 -14,80 -5,15 -3,00
Dividend per share8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: Baker Tilly

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Epigenomics
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
A37FT4 DE000A37FT41 AG 0,97 Mio € 19.07.2004 9F4MG9F8+6P
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
-0,99 0,00 0,00 -0,02 -0,12 -0,17 2,87
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,00 0,00 0,00 0,00%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
29.05.2024 30.09.2024 14.03.2024
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
-17,16%
1,11 €
ATH 6.236,80 €
+10,41% +5,23% -40,32% -40,80% -99,92%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL